Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Jiangsu Recbio Technology Co., Ltd.
江蘇瑞科生物技術股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2179)

VOLUNTARY ANNOUNCEMENT

ADDITION TO THE DRUG PRODUCTION LICENSE FOR THE RECOMBINANT SHINGLES VACCINE BEING GRANTED TO THE COMPANY

This announcement is made by Jiangsu Recbio Technology Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") on voluntary basis. The board of directors of the Company (the "**Board**") is pleased to announce that the Company has recently obtained the approval for the addition to the Drug Production License issued by the Jiangsu Provincial Drug Administration, pursuant to which the recombinant shingles vaccine (CHO cell) and relevant adjuvant components are added to the scope of production (the "**Addition**"). The Addition marks that the Group has achieved further expansion of its R&D and production capabilities in the field of preventive biological products, laying a solid foundation for the subsequent marketing and registration of the drug.

I. Basic Information on the Addition to Drug Production License

- **Enterprise name**: Jiangsu Recbio Technology Co., Ltd.
- **License No.**: 蘇 20210057
- **Issuing authority**: Jiangsu Provincial Drug Administration
- **Effective date**: November 5, 2025
- **Expiry of validity**: November 14, 2026

- **Additional address and scope of production**:

  - Buildings 28 and 29, No. 20, Xiushui Road, Pharmaceutical HDTZ, Taizhou, Jiangsu Province: preventive biological product "recombinant shingles vaccine (CHO cell)", including the shingles bulk production line in the CHO cell bulk production workshop, the BFA01 adjuvant production line in the adjuvant production workshop, and the vial repackaging production line in the repackaging workshop;

  - Building 26, No. 20, Xiushui Road, Pharmaceutical HDTZ, Taizhou, Jiangsu Province: preventive biological product "recombinant shingles vaccine (CHO cell) adjuvant component Monophosphoryl Lipid A (MPL)", including the adjuvant component production line (MPL) in the adjuvant component production workshop (Monophosphoryl Lipid A);

  - No. 888, Yaocheng Avenue, Pharmaceutical HDTZ, Taizhou, Jiangsu Province: additional functions of serving as warehouses and laboratories.

    (The above scope of production is limited to the purpose of registration application)

II. Product and Technology Advantages

The recombinant shingles vaccine (CHO cell) developed by the Group incorporates the self-developed BFA01 liposomal adjuvant system, exhibits excellent safety and immunogenicity, and aligns with the technology iteration trend of next-generation vaccines. Shingles is a common infectious disease among middle-aged and elderly populations. With the acceleration of population aging, the market demand for relevant vaccines has maintained sustained growth. The advancement of the development and production of this product is expected to provide more high-quality preventive options for clinical practice.

III. Impact on the Group

The Addition affirms the drug regulatory authority's recognition of the Group's quality management system and production capabilities. The Group has established production workshops to the international standard, and completed relevant process validation, enabling the Group to possess large-scale production capacity for the recombinant shingles vaccine. The Addition will facilitate the Group's further optimization of its vaccine product portfolio, and enhancement of its overall competitiveness in the biopharmaceutical sector, thus providing critical support for the future commercialization of the product.

The Group will remain committed to advancing the R&D and registration of vaccine products, contributing to public health and the enhancement of shareholder value.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Jiangsu Recbio Technology Co., Ltd.
Dr. LIU Yong
Chairman

Jiangsu Province, the PRC, November 14, 2025

As at the date of this announcement, the Board comprises Dr. LIU Yong as the chairman of the Board and an executive director, Mr. LI Bu, Ms. CHEN Qingqing and Dr. HONG Kunxue as executive directors, Dr. WANG Ruwei, Dr. ZHANG Jiaxin, Dr. ZHOU Hongbin and Mr. HU Houwei as non-executive directors, and Dr. XIA Lijun, Mr. LIANG Guodong, Professor GAO Feng and Professor YUEN Ming Fai as independent non-executive directors.